This site is intended for health professionals only

Orion to apply for marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family


Orion Corporation is developing a budesonide-formoterol formulation combining budesonide as an anti-inflammatory agent and formoterol as a long-acting bronchodilator to expand the range of the inhalable Easyhaler® drug product family for treatment of asthma and COPD.
Based on the favourable pharmacokinetic study results of this Easyhaler-developement programme Orion is planning to apply for a marketing authorisation for the combined budesonide-formoterol formulation. Orion currently estimates that the marketing authorisation application would be submitted in Europe during the first half of 2013.

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine